X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2012 October 24, 2012 arGEN-X appoints Dr. David L. Lacey to its supervisory board October 3, 2012 RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody May 13, 2012 Cambridge Healthtech Associates™ Announces arGEN-X as Inaugural Signature Award™ Winner April 23, 2012 arGEN-X granted first US patent covering its unique NHance™ technology March 18, 2012 arGEN-X launches NHance™ technology to generate better human antibody therapies March 18, 2012 arGEN-X appoints Alain Thibault as Chief Medical Officer and Koos Rasser as IP Counsel February 27, 2012 arGEN-X enters into a therapeutic antibody alliance with Shire February 7, 2012 arGEN-X advances a third therapeutic antibody program into preclinical development 2011 November 30, 2011 arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B round November 29, 2011 arGEN-X is awarded €1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets September 6, 2011 arGEN-X presents significant progress at Biopharm America 2011 July 25, 2011 arGEN-X announces non-exclusive license with BioWa for Potelligent® technology Pagination First page « First Previous page ‹ Previous … Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Current page 31 Page 32 Next page Next › Last page Last »